Inhibition of miR-128 Abates Aβ-Mediated Cytotoxicity by Targeting PPAR-γ via NF-κB Inactivation in Primary Mouse Cortical Neurons and Neuro2a Cells |
Geng, Lijiao
(Department of Rehabilitation Medicine, Huaihe Hospital of Henan University)
Zhang, Tao (Department of Neurology, Huaihe Hospital of Henan University) Liu, Wei (Department of Neurology, Huaihe Hospital of Henan University) Chen, Yong (Department of Rehabilitation Medicine, Huaihe Hospital of Henan University) |
1 | Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016;12:459-509. DOI |
2 | Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014;88:640-51. DOI |
3 | Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1997;94:2642-7. DOI |
4 | Lezana JP, Dagan SY, Robinson A, Goldstein RS, Fainzilber M, Bronfman FC, et al. Axonal promotes neuronal regeneration after injury. Dev Neurobiol 2016;76:688-701. DOI |
5 | Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep 2015;67:195-203. DOI |
6 | Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, et al. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 2006;23:1711-20. DOI |
7 | Lin W, Ding M, Xue J, Leng W. The role of TLR2/JNK/ pathway in amyloid peptide-induced inflammatory response in mouse NG108-15 neural cells. Int Immunopharmacol 2013;17:880-4. DOI |
8 | Villapol S. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell Mol Neurobiol 2018;38:121-32. DOI |
9 | Corona JC, Duchen MR. as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med 2016;100:153-63. DOI |
10 | Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008;5:481-9. DOI |
11 | Toba J, Nikkuni M, Ishizeki M, Yoshii A, Watamura N, Inoue T, et al. agonist pioglitazone improves cerebellar dysfunction at pre- deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice. Biochem Biophys Res Commun 2016;473:1039-44. DOI |
12 | Memet S. NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol 2006;72:1180-95. DOI |
13 | Kim DH, Yeo SH, Park JM, Choi JY, Lee TH, Park SY, et al. Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene 2014;545:185-93. DOI |
14 | Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016;8:595-608. DOI |
15 | Kang S, Lee YH, Lee JE. Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Med J 2017;58:479-88. DOI |
16 | Shi ZM, Han YW, Han XH, Zhang K, Chang YN, Hu ZM, et al. Upstream regulators and downstream effectors of in Alzheimer's disease. J Neurol Sci 2016;366:127-34. DOI |
17 | Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 2009;7:147-54. DOI |
18 | Karnati HK, Panigrahi MK, Gutti RK, Greig NH, Tamargo IA. miRNAs: key players in neurodegenerative disorders and epilepsy. J Alzheimers Dis 2015;48:563-80. DOI |
19 | Adlakha YK, Saini N. Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer 2014;13:33. DOI |
20 | Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007;18:297-300. DOI |
21 | Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 2014;35:152-8. DOI |
22 | Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008;22:1-14. DOI |
23 | Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004;24:10908-17. DOI |
24 | Kitamura Y, Shimohama S, Koike H, Kakimura Ji, Matsuoka Y, Nomura Y, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 1999;254:582-6. DOI |
25 | Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 2005;304:91-104. DOI |
26 | Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003;23:9796-804. DOI |
27 | d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 2005;391(Pt 3):693-8. DOI |
28 | de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006;9:167-81. DOI |
29 | Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000;20:558-67. DOI |
30 | Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006;103:443-8. DOI |
31 | Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR- pathway. Neuropharmacology 2012;63:653-66. DOI |
32 | Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-29. DOI |
33 | Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, et al. Peroxisome proliferator-activated receptor gamma (PPAR-) and neurodegenerative disorders. Mol Neurobiol 2012;46:114-24. DOI |
34 | Schmidt K. Clinical dementia rating scale. In: Michalos AC, editor. Encyclopedia of quality of life and well-being research. Dordrecht: Springer; 2014. p.957-60. |
35 | Mitchell AJ. The Mini-Mental State Examination (MMSE): update on its diagnostic accuracy and clinical utility for cognitive disorders. In: Larner AJ, editor. Cognitive screening instruments. Cham: Springer; 2017. p.37-48. |
36 | Krichevsky AM, Kosik KS. Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 2001;32:683-96. DOI |
37 | Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid- precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 2012;287:31298-310. DOI |
38 | Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, et al. A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease. Biochem Biophys Res Commun 2017;483:1156-65. DOI |
39 | Femminella GD, Ferrara N, Rengo G. The emerging role of microRNAs in Alzheimer's disease. Front Physiol 2015;6:40. |
40 | Millan MJ. Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: an integrative review. Prog Neurobiol 2017;156:1-68. DOI |
41 | Guidi M, Muinos-Gimeno M, Kagerbauer B, Marti E, Estivill X, Espinosa-Parrilla Y. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SHSY5Y neuroblastoma cells. BMC Mol Biol 2010;11:95. DOI |
42 | Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tauphosphorylation, and apoptosis in postmitotic neurons. J Neurosci 2013;33:14645-59. DOI |
43 | McSweeney KM, Gussow AB, Bradrick SS, Dugger SA, Gelfman S, Wang Q, et al. Inhibition of microRNA 128 promotes excitability of cultured cortical neuronal networks. Genome Res 2016;26:1411-6. DOI |
44 | Tiribuzi R, Crispoltoni L, Porcellati S, Di Lullo M, Florenzano F, Pirro M, et al. miR128 up-regulation correlates with impaired amyloid (1-42) degradation in monocytes from patients with sporadic Alzheimer's disease. Neurobiol Aging 2014;35:345-56. DOI |